Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
Journal of Neurogastroenterology and Motility
;
: 141-151, 2014.
Article
in English
| WPRIM
| ID: wpr-87491
ABSTRACT
Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quality of Life
/
Population Characteristics
/
Bile
/
Health Care Costs
/
Serotonin Receptor Agonists
/
Constipation
/
Irritable Bowel Syndrome
/
Laxatives
/
Lubiprostone
Type of study:
Prognostic study
Language:
English
Journal:
Journal of Neurogastroenterology and Motility
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS